1. EXECUTIVE SUMMARY
Go Life International is a class leading multinational nutraceutical and cosmeceutical company
According to Frost & Sullivan – (A leading market research and analyst company) - nutraceutical and cosmeceutical industry - expected to reach USD 500 billion in 2018
Concurrent with the analysis by Frost & Sullivan, Go Life has experienced exponential sales growth since 2005
Our products are formulated using unique patent protected
technology and know-how
Go Life has the depth of skills and experience to significantly
increase its share of the domestic market, and launch / establish
its product range in key International markets

2. EXECUTIVE SUMMARY
Are fully integrated business model encompasses in-house research, product development, superior quality products with
global appeal
Go Life listed on Stock Exchange of Mauritius in 2011 and has approval for listing on the AltX of the Johannesburg Stock Exchange by Q2 of 2015

3. COMPANY HISTORY
2005
Dr. Henry Davis – Inventor of Gotha products –widely acknowledged efficacy - unique patented products
2006
Robert Matzner – Founder of Gotha - exclusive distribution of
Gotha products
2008
Gerhard Naude – Founder of Go Life, rebranding, and market expansion
7 July 2011
Listing of Go Life on the Stock Exchange of Mauritius

4. COMPANY HISTORY
2011
Dr Wolfgang Schoenfeld – Founded Solmic Research based on
a unique range of products –marketed through Sodocos GmbH
2015
Listing of GoLife on AltX of the Johannesburg Stock Exchange

5. MILESTONES
2008
Establishment of Go Life
2011
Purchase of Gotha
7 July 2011
Listing of Go Life on the Stock Exchange of Mauritius
May – June 2014
Start negotiations with German counter parts in the nutraceutical field
Establishment of Go Life Global - assisted by German parties, Solmic and Sodocos

6. Decision to list on the AltX of the Johannesburg Stock Exchange
MILESTONES
September 2014
Decision to list on the AltX of the Johannesburg
Stock Exchange
September 2014
Decision to list on the AltX of the Johannesburg
Stock Exchange

7. MILESTONES
October-December 2014
Formation of new Go Life Global Group
January 2015
Approval of proposed Global Business Plan of the global group of Go Life, by the JSE
Presentation of Go Life to the Advisory Committee of the AltX
Approval by Advisory Committee to proceed with AltX listing
25 March 2015
Proposed date of listing on AltX of the JSE

8. COMPANY STRUCTURE Distribution Research Development Manufacturing 100%
22%
Research
Development
Manufacturing
Distribution
78%
50%
100%
100%
100%
100%

9. THE BUSINESS Health Sector
Life Sciences focus on Nutraceuticals and Cosmeceuticals
Fully integrated company covering research, development,
manufacturing, marketing of high quality health products
IP : strong patent portfolio and proprietary know-how
Tangible assets: properties: frail care centres
Operational Sites: South Africa, EU and USA

10. KEY TEAM MEMBERS Gerhard Naude CEO Go Life International Limited
Dr. Wolfgang Schoenfeld CEO Go Life Global
Marthinus Wolmarans CFO Go Life International
Greg Gilbert Research & Business Development
Dr. Lana Du Plessis Research & Development
Grant Ramanauth Non- Executive Director
Extensive experience in management of people and companies
Strong financial and operational background
Scientific excellence

11. MARKETS Nutraceuticals Cosmeceuticals
More than food and cosmetics,
natural extracts, vitamins, co-factors, essential oils
Efficacy closer to pharmaceuticals, safety closer or identical to food and cosmetics
Provide health and medicinal benefits including prevention and treatment of diseases
Increase life expectancy and quality of life -
a daily necessity for an active and healthy lifestyle
Scienctific knowledge and proven data and processes necessary for product efficacy, marketing success and regulatory approvals
Combined market size to reach 500 Bill US$ by 2018

12. Compound annual growth of 7%
MARKETS
Market for health supporting products growing significantly faster than Global GDP
Phenomenon the result of increased health awareness, aging population and rapid expansion of global middle class
Nutraceuticals
Compound annual growth of 7%
Cosmetics
Growth of cosmeceuticals will outperform growth of cosmetics
Cosmeceutical market increasing annually by approx. 8%
Fredonia Marketing Research 2011

13. TECHNOLOGY BACKGROUND
Go Life’s success is founded on:
Patented technologies, products, ingredients and proprietary
formulas
Extensive knowledge and exceptional product innovation
Established marketing routes and distribution networks
Key proprietary advantage – technology to dramatically increase
Bioavailability and absorption of compounds

14. TECHNOLOGY BACKGROUND (continued)
Without water, there is NO life:
Evolution has optimized the uptake of substances
into the body based on water soluble ingredients
Fat soluble ingredients, e.g. vitamins A, D, E, Cofactor Q10 and essential Omega 3-fatty acids are poorly absorbed by the intestinal tract: uptake lower than 10% ; 90% excreted
Low bioavailability = High dosing required, thus increase in costs, taste problems and gastrointestinal issues.
Many products overdosed, poor tasting with little efficacy
Many natural ingredients and extracts are unstable and
insoluble

15. INCREASING BIO-AVAILABILITY
Making active ingredients water soluble
e.g. Vitamin A, D, E, CoQ10, resins, extracts
Mimicking the natural process or food absorption based on bile salt mediated uptake (“Micellation”)
More efficient and versatile than competitor technologies

16. THE CHALLENGE EXAMPLE -Vit D
Vitamin D – more than a bone hormone, 80% of all cells react to Vitamin D – yet 70% of entire population Vitamin D deficient
Winter depression low vitamin D levels
due to low sun exposure
Host defence enhancement of natural
resistance to infection
Cardiac function enhancement of heart function
Cancer clear evidence of activity in certain cancers e.g. breast cancer

17. OUR CORE ASSETS
Know-How and IP
- patent portfolio covering Go Life’s technology
- internal know-how on technologies and unique formulations
Strong expertise in research and development
- understanding biochemistry and medicine
- understanding the mechanism of action between ingredients
- expertise in preclinical and clinical trials
- strong link to scientific community
Extensive experience in manufacturing
- in-house preparation of extracts
- production of intermediates and final products

18. OUR ASSETS
Close contact with Customers and the Medical Community (Pharmacists, Therapists, Physicians
Health Care Workers)
Extensive experience in medical product marketing (flyers, background literature, brochures etc.)
Thorough understanding of regulatory environment
in EU, US and SA
- in SA all products are registered with MCC

19. Setting up solid base for future projections
THE FINANCIALS
The basis of our projections
Products currently marketed in SA and EU
Experience in the US market
Production and product costs clearly established
Cost of company acquisitions are fixed
Company overhead-structure costs in SA,
EU and US in-line with historical cost
Setting up solid base for future projections

20. Testing sensitivity of the model
THE FINANCIALS
Extrapolation of existing market values
Addressing individual marketing channels
e.g. US: direct marketing; SA: major retail chains
Addressing initial significant marketing costs
Addressing continuous development of products
Conservative growth estimates
Testing sensitivity of the model
identifying key parameters and go´s and no go´s for EBIT/Cashflow P/L

21. ACQUISITIONS
All companies in the group were acquired by means of Vendor
and lockup shares at USD 10c per share from Go Life and
registered in the temporary share register in South Africa
- Vendor Shares - shares that can be sold by the vendor
Lockup Shares - shares that the vendor can sell, at certain time intervals

22. Financials

23. Financials

24. Financials

25. Financials
2014
2015
2016
2017
Revenues
3.8
10.9
27.2
58.7
Cost of sales
769.5
10.1
20.8
Gross profit
3.0
7.0
17.1
37.9
Operational expenses
1.9
6.7
13.0
22.7
Pre tax income
1.5
429.3
4.2
15.4

26. RATIONALE FOR LISTING
Global investors would prefer to invest into a more liquid and wider recognised Stock Exchange like the AltX of the Johannesburg Stock Exchange
South African investors are precluded from investing in current offshore structure
The new dual listing will accommodate South African and international investors

27. PROSPECTS
Marketing spend i.r.o the globalisation of the existing brands will provide benefits across the group
Existing registration at local authorities will pave the way for marketing new products and entering new markets
Continous research and development of products will be
boosted by existing and newly established laboratories in
Germany and South Africa
Production will decentralise – close to individual distribution and marketing channels
Close interaction beween the sites will ensure highest
product quality and global sustainability

28. CONTACTS Gerhard Naude Mobile: +27 82 495 4647
Wolfgang Schoenfeld
Mobile: